Non-small Cell Lung Cancer Stage IV
Conditions
Keywords
Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung* / diagnosis, Carcinoma, Non-Small-Cell Lung* / genetics, Precision Medicine, Pathology, Molecular, Patient Reported Outcome Measures, Database Management Systems
Brief summary
The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.
Detailed description
The aim of the DigiNet project is to prospectively evaluate a precision medicine program for lung cancer and to improve personalized care of patients with advanced non-small cell lung cancer (NSCLC) through a collaboration of specialized academic centers with routine care providers (hospitals, oncology practices). The use of targeted therapies will be regularly monitored and guided through a shared digital database. Patients with an initial diagnosis of stage IV NSCLC in the study regions (study region east: Berlin and Saxony; study region west: North Rhine-Westphalia) are included. DigiNet builds on the foundations and structures of the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, which provides molecular diagnostics and treatment information to the participating physicians based on the latest evidence. Within the framework of DigiNet, patients are regularly consulted by the study practitioners and the clinical data is documented in a structured manner in a central project database. Through the digital collaboration of the nNGM network centers via the shared project database with the practitioners in routine care, continuous monitoring of the course of treatment and, in the case of critical conditions, treatment guidance by an expert committee advising the practitioner is provided. In addition, the patients routinely assess the quality of life (EORTC QLQ-C30, EORTC QLQ-LC29, EQ-5D), as well as anxiety and depression (PHQ-4). The results of these patient-reported outcomes (PROs) are incorporated into the treatment by the practitioners (patient-centered treatment approach). The evaluation of the project is structured into different core domains: An evaluation of clinical endpoints, process parameters (implementation of the intervention), and health economic evaluations will be conducted. The acceptance and potential for improvement of the project will be assessed through qualitative interviews with the stakeholders. Data from the state cancer registries of the study regions will be incorporated to generate a population-based comparative cohort for the evaluation of the main research questions of DigiNet, thereby representing patients receiving routine care in Germany.
Interventions
OTHERDigiNet intervention
Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions: * broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer * regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians * monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression * incorporation of PROs into treatment by physicians * treatment monitoring and counseling in the case of critical conditions by expert committee
Sponsors
Gemeinsamer Bundesausschuss (G-BA)
AOK Rheinland/Hamburg
AOK Nordwest
BARMER
University Hospital, Essen
Charite University, Berlin, Germany
Berlin Institute of Health
Helios Klinikum Emil von Behring
University Hospital Carl Gustav Carus
Deutsche Krebsgesellschaft e.V.
Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V.
AOK Bundesverband
FOM Hochschule für Oekonomie und Management
University Medicine Greifswald
Technische Universität Dresden
University of Cologne
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with advanced NSCLC, stage IV * Age \> 18 years * Life expectancy at least 4 weeks (initial assessment at inclusion in nNGM and confirmation at baseline (implementation of treatment decision))
Exclusion criteria
* Missing informed consent * Illnesses and behaviors that impair compliance (e.g., dementia, addictive disorders) * Severely impaired general physical condition that no longer permits therapy for lung cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | up to 34 months | Overall Survival (OS) will be assessed in months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time on First Treatment (ToT) | up to 34 months | Duration under first-line therapy will be assessed in months. |
| Hospitalization rate | up to 34 months | Frequency of hospital stays will be assessed using health insurance data. |
| Quality of Life (EORTC QLQ-C30) | up to 34 months | Quality of Life (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire, EORTC QLQ-C30) will be assessed in absolute values and change over time. Each item is rated on a response scale 1 = not at all to 4 = very much with exception of the last two items, which assess overall health and quality of life on a scale from 1 = very poor to 7 = excellent. All EORTC QLQ-C30 scale scores range from 0 to 100, whereby higher scores on a functional scale indicate a high level of functioning, whereas higher scores on a symptom scale/symptom item indicate greater symptom burden. |
| Quality of Life (EORTC QLQ-LC29) | up to 34 months | Quality of Life (European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer, EORTC QLQ-LC29) will be assessed in absolute values and change over time. Each item is rated on a response scale 1 = not at all to 4 = very much and refer to the time frame during the past week. All EORTC QLQ-LC29 scale scores range from 0 to 100, whereby higher scores for a symptom scale/symptom item indicate greater symptom burden. |
| Symptoms of anxiety (GAD-2) | up to 34 months | Symptoms of anxiety (Generalized Anxiety Disorder Scale-2, GAD-2) will be assessed in absolute values and change over time. Each item is rated on a response scale 0 = not at all to 3 = nearly every day and refer to the time frame during the past two weeks. Higher scores indicate greater symptom burden. |
| Symptoms of depression (PHQ-2) | up to 34 months | Symptoms of depression (Patient-Health-Questionnaire-2, PHQ-2) will be assessed in absolute values and change over time. Each item is rated on a response scale 0 = not at all to 3 = nearly every day and refer to the time frame during the past two weeks. Higher scores indicate greater symptom burden. |
| Frequency of applied targeted molecular therapies based on clinical therapy information from the MURIEL database | up to 34 months | The frequency of applied targeted molecular therapies is based on clinical therapy information from the MURIEL database. |
| Progression-Free Survival (PFS) | up to 34 months | Progression-Free Survival (PFS) will be assessed in months. |
| Completeness of the documentation of the treatment course | up to 34 months | Assessing the completeness of the documentation of the treatment course (DigiNet study visits) in %. |
| Frequency of patients' completing the PROs | up to 34 months | Assessing the frequency of patients' completing the patient-reported outcomes (PRO) via the internet portal |
| Cost-effectiveness of DigiNet compared to standard care in terms of incremental costs per life years gained | up to 34 months | Assessing the cost-effectiveness of DigiNet compared to standard care in terms of incremental costs per life years gained |
| Cost-effectiveness of DigiNet compared to standard care in terms of costs per quality-adjusted life year [QALY] | up to 34 months | Assessing the cost-effectiveness of DigiNet compared to standard care in terms of costs per quality-adjusted life year \[QALY\] |
| Cost of implementation related to DigiNet from the service provider perspective (hospital, practices) | up to 34 months | Assessing the cost of implementation related to DigiNet from the service provider perspective (hospital, practices) in Euro (€) |
| Process costs related to DigiNet from the service provider perspective (hospital, practices) | up to 34 months | Assessing the process costs related to DigiNet from the service provider perspective (hospital, practices) in Euro (€) |
| Formative evaluation | up to 34 months | Formative evaluation regarding the implementation will be conducted using qualitative analysis of semi-structured interviews |
| Frequency of active contact of the expert advisory board with physicians during the course of treatment | up to 34 months | Assessing the frequency of the expert advisory board actively contacting physicians during the course of treatment |
Countries
Germany
Outcome results
None listed